| Drug General Information |
| Drug ID |
D0E0NM
|
| Former ID |
DNCL002117
|
| Drug Name |
DCC-2036
|
| Drug Type |
Small molecular drug
|
| Indication |
Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0]
|
Phase 1 |
[1]
|
|---|
| Company |
Deciphera Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C30H28FN7O3
|
| Canonical SMILES |
CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)<br />C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
|
| InChI |
1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
|
| InChIKey |
WVXNSAVVKYZVOE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
56403339, 57548987, 123055185, 123055186, 123058785, 124958086, 136349530, 136367661, 136920318, 137276016, 144115890, 160644569, 162011946, 162037711, 162108915, 162202690, 163620736, 163686053, 164045127, 170483879, 170483880, 172232428, 185990477, 189622837, 198983986, 223389164, 223705271, 228188520, 245535818, 249814481, 252110192, 252110222, 252160750, 252216186, 252451795
|
| Target and Pathway |
| Target(s) |
Proto-oncogene c-Abl |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Cell cycle
|
|
Axon guidance
|
|
Neurotrophin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
Viral myocarditis
|
|
PANTHER Pathway
|
Axon guidance mediated by Slit/Robo
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
ATM pathway
|
|
Regulation of Telomerase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
PDGFR-beta signaling pathway
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Regulation of actin dynamics for phagocytic cup formation
|
|
CDO in myogenesis
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
HDR through Single Strand Annealing (SSA)
|
|
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by Robo receptor
|
|
Myogenesis
|
|
Factors involved in megakaryocyte development and platelet production
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00827138) Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation). U.S. National Institutes of Health. |
|---|
